The rationale behind this approach is to first simultaneously deplete cancer-associated fibroblasts (CAFs), which are a major aspect of the tumour stroma, while inhibiting CXCR4-mediated immune suppression [145,146,147,148]. The gene discussed is CXCR4; the disease is neoplasm.